Drug Trial Radar · NCT06411379
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
418
Actual
Start
May 14, 2024
Primary completion
Aug 14, 2025
Study completion May 20, 2026
Sponsor
- Lead sponsor
- MoonLake Immunotherapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.
Conditions
- Hidradenitis Suppurativa
Interventions
SonelokimabDrug
Sonelokimab
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hidradenitis Suppurativa Clinical Response 75Time frame: Week 16
Locations
106 sites in 12 countries. Site status is shown where the registry gives one.
Clinical Site
Birmingham, Alabama
Clinical Site
North Little Rock, Arkansas
Clinical Site
Fountain Valley, California
Clinical Site
Santa Monica, California
Clinical Site
Aventura, Florida
Clinical Site
Hialeah, Florida
Clinical Site
Miami, Florida
Clinical Site
Ocala, Florida
Clinical Site
Tampa, Florida
Clinical Site
Skokie, Illinois
Clinical Site
Plainfield, Indiana
Clinical Site
Murray, Kentucky
Clinical Site
Baton Rouge, Louisiana
Clinical Site
Baltimore, Maryland
Clinical Site
Ann Arbor, Michigan
Clinical Site
Canton, Michigan
Clinical Site
Clarkston, Michigan
Clinical Site
Waterford, Michigan
Clinical Site
New Brighton, Minnesota
Clinical Site
Omaha, Nebraska
Clinical Site
Las Vegas, Nevada
Clinical Site
New York, New York
Clinical Site
Fargo, North Dakota
Clinical Site
Columbus, Ohio
Clinical Site
Murfreesboro, Tennessee
Clinical Site
Dallas, Texas
Clinical Site
Plano, Texas
Clinical Site
San Antonio, Texas
Clinical Site
Morgantown, West Virginia
Clinical Site
Milwaukee, Wisconsin
Clinical Site
Ghent, Belgium
Clinical Site
Leuven, Belgium
Clinical Site
Liège, Belgium
Clinical Site
Woluwe-Saint-Lambert, Belgium
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Stara Zagora, Bulgaria
Clinical Site
Calgary, Alberta, Canada
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.